<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-11-18" updated="2020-01-02">
  <drugbank-id primary="true">DB05445</drugbank-id>
  <name>TA-NIC</name>
  <description>TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive reward associated with smoking.</description>
  <cas-number/>
  <unii/>
  <state>liquid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3497</ref-id>
        <pubmed-id>17288232</pubmed-id>
        <citation>Goniewicz ML, Koszowski B, Czogala J, Zymelka A: [New prospects of nicotine dependence treatment--vaccines]. Przegl Lek. 2006;63(10):1114-8.</citation>
      </article>
      <article>
        <ref-id>A3498</ref-id>
        <pubmed-id>15648190</pubmed-id>
        <citation>Cerny T: Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167-75.</citation>
      </article>
      <article>
        <ref-id>A3499</ref-id>
        <pubmed-id>15270640</pubmed-id>
        <citation>Authors unspecified: Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines. 2004 Aug;3(4):386.</citation>
      </article>
      <article>
        <ref-id>A3500</ref-id>
        <pubmed-id>8132774</pubmed-id>
        <citation>Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in tobacco dependence.</indication>
  <pharmacodynamics>Raises anti-nicotine antibodies in order to reduce the activity of reward mechanisms associated with nicotine addiction.</pharmacodynamics>
  <mechanism-of-action>Reduces nicotine entry into the brain and thus decreases activation of neural reward pathways associated with addiction to smoking.</mechanism-of-action>
  <toxicity>Appears to be well-tolerated.</toxicity>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding>TA-NIC consists of nicotine conjugated to the carrier protein rCTB and an aluminium adjuvant.</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Biological Products</category>
      <mesh-id>D001688</mesh-id>
    </category>
    <category>
      <category>Complex Mixtures</category>
      <mesh-id>D045424</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>515.703</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C26H45NO7S</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910143</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>TA-NIC</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>